Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)

NCT04161898 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04161898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04161898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 4, 2020
Completion date
August 31, 2028
Enrollment
56 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

takayasu arteritis (tak)